Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Growth Metrics

Northwest Biotherapeutics (NWBO) Non-Current Deffered Revenue (2018)

Northwest Biotherapeutics' Non-Current Deffered Revenue history spans 1 years, with the latest figure at $4.8 million for Q4 2018.

Quarterly results put Non-Current Deffered Revenue at $4.8 million for Q4 2018, changed N/A from a year ago — trailing twelve months through Dec 2018 was $4.8 million (changed N/A YoY), and the annual figure for FY2018 was $4.8 million, changed.
Non-Current Deffered Revenue for Q4 2018 was $4.8 million at Northwest Biotherapeutics.
In the past five years, Non-Current Deffered Revenue ranged from a high of $4.8 million in Q4 2018 to a low of $4.8 million in Q4 2018.